Maravai LifeSciences (NASDAQ:MRVI) CEO Bernd Brust Purchases 93,358 Shares of Stock

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) CEO Bernd Brust purchased 93,358 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was bought at an average cost of $3.21 per share, with a total value of $299,679.18. Following the acquisition, the chief executive officer owned 250,559 shares of the company’s stock, valued at approximately $804,294.39. The trade was a 59.39% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Bernd Brust also recently made the following trade(s):

• On Tuesday, November 11th, Bernd Brust acquired 157,201 shares of Maravai LifeSciences stock. The shares were bought at an average cost of $3.24 per share, for a total transaction of $509,331.24.

Maravai LifeSciences Trading Up 6.6%

Shares of MRVI stock traded up $0.22 on Friday, hitting $3.47. 562,369 shares of the stock traded hands, compared to its average volume of 2,132,394. The company has a debt-to-equity ratio of 0.74, a quick ratio of 4.49 and a current ratio of 5.29. Maravai LifeSciences Holdings, Inc. has a twelve month low of $1.66 and a twelve month high of $6.21. The firm’s 50-day moving average price is $3.03 and its two-hundred day moving average price is $2.58. The stock has a market capitalization of $884.82 million, a PE ratio of -4.13 and a beta of 0.34.

Maravai LifeSciences (NASDAQ:MRVI) last issued its earnings results on Thursday, November 6th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). The firm had revenue of $41.63 million for the quarter, compared to analysts’ expectations of $49.02 million. Maravai LifeSciences had a negative return on equity of 22.42% and a negative net margin of 62.88%. As a group, analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current year.

Analyst Ratings Changes

A number of analysts recently issued reports on MRVI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Maravai LifeSciences in a research report on Tuesday, October 14th. Royal Bank Of Canada reduced their price target on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 12th. Three equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $5.22.

Institutional Investors Weigh In On Maravai LifeSciences

A number of hedge funds have recently added to or reduced their stakes in the business. Callan Family Office LLC acquired a new position in shares of Maravai LifeSciences in the second quarter worth $25,000. Ethic Inc. purchased a new position in Maravai LifeSciences in the second quarter valued at $26,000. Sprott Inc. acquired a new position in Maravai LifeSciences during the 3rd quarter worth $29,000. McAdam LLC acquired a new position in Maravai LifeSciences during the 1st quarter worth $31,000. Finally, EntryPoint Capital LLC purchased a new stake in Maravai LifeSciences during the 1st quarter worth about $32,000. 50.25% of the stock is currently owned by institutional investors and hedge funds.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.